EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function

Kristine M Erlandson iD, Triin Umbleja, Heather J Ribaudo, Jennifer A Schrack, Edgar T Overton, Carl J Fichtenbaum, Kathleen V Fitch, Jhoanna C Roa, Marissa R Diggs, Kenneth Wood, Markella V Zanni, Gerald S Bloomfield und 8 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae422 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Kristine M Erlandson und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Quinolines, Hydroxymethylglutaryl-CoA Reductase Inhibitors, HIV Infections, Cardiovascular Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, ACTG Laboratory Center, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Little is known about the potential benefits or harms of statins on physical function among people with human immunodeficiency virus (PWH).

Methods

REPRIEVE was a double-blind randomized controlled trial evaluating pitavastatin for primary prevention of major adverse cardiovascular events in PWH. Time to complete 10 chair rises, 4-m gait speed, grip strength, and a modified short physical performance test were assessed annually for up to 5 years in the ancillary study PREPARE and analyzed using linear mixed models.

Findings

Of 602 PWH, 52% were randomized to pitavastatin and 48% to placebo. Median age was 51 years; 18% were female at birth; 2% transgender; and 40% Black, and 18% Hispanic. Median PREPARE follow-up was 4.7 (4.3–5.0) years. Muscle symptoms (grade ≥3 or treatment-limiting) occurred in 5% of both groups. There was no evidence of decline in chair rise rate in either treatment group and no difference in the pitavastatin group compared to placebo (estimated difference −0.10 [95% confidence interval, −.30 to 0.10] rises/min/year; P = .31). Small declines over time were observed in other physical function tests in both treatment groups, with no apparent differences between groups.

Interpretation

We observed minimal declines in physical function over 5 years of follow-up among middle-aged PWH, with no differences among PWH randomized to pitavastatin compared to placebo. This finding, combined with low prevalence of myalgias, supports the long-term safety of statin therapy on physical function, when used for primary prevention of major adverse cardiovascular events among PWH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesHydroxymethylglutaryl-CoA Reductase InhibitorsHIV InfectionsCardiovascular DiseasesHumansFemaleMaleMiddle AgedDouble-Blind MethodAdultAged

Stichwörter der Autor:innen

HIVfrailtymusclephysical functionstatin

Substanzen

pitavastatinQuinolinesHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA.
  • Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.
  • Center on Aging and Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Department of Medicine, University of Alabama Birmingham School of Medicine, Birmingham, Alabama, USA.
  • ViiV Healthcare Medical Affairs, Durham, North Carolina, USA.
  • Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

ORCID-Profile: Kristine M Erlandson

Förderung

  • NIDDK NIH HHS
  • ACTG Laboratory Center
  • NIAID NIH HHS
  • Gilead Sciences
  • ViiV Healthcare
  • NHLBI NIH HHS
  • Clinical Coordinating Center
  • NCATS NIH HHS

Zitieren

APA

Erlandson, K. M., Umbleja, T., Ribaudo, H. J., Schrack, J. A., Overton, E. T., Fichtenbaum, C. J., Fitch, K. V., Roa, J. C., Diggs, M. R., Wood, K., Zanni, M. V., Bloomfield, G. S., Malvestutto, C., Aberg, J. A., Rodriguez-Barradas, M. C., Morones, R. G., Breaux, K., Douglas, P. S., Grinspoon, S. K., & Brown, T. T. (2025). Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae422

Vancouver

Erlandson KM, Umbleja T, Ribaudo HJ, Schrack JA, Overton ET, Fichtenbaum CJ, et al. Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae422

BibTeX
@article{Erlandson2025,
  author = {Erlandson, Kristine M and Umbleja, Triin and Ribaudo, Heather J and Schrack, Jennifer A and Overton, Edgar T and Fichtenbaum, Carl J and Fitch, Kathleen V and Roa, Jhoanna C and Diggs, Marissa R and Wood, Kenneth and Zanni, Markella V and Bloomfield, Gerald S and Malvestutto, Carlos and Aberg, Judith A and Rodriguez-Barradas, Maria C and Morones, Rosalba Gomez and Breaux, Katherine and Douglas, Pamela S and Grinspoon, Steven K and Brown, Todd T},
  title = {Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae422}
}
Kostenlos starten →